Multiomics analysis of secondary loss of response to infliximab in patients with Crohn's disease

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300073194

Enrollment

Unknown

Registered

2023-07-04

Start date

2023-07-05

Completion date

Unknown

Last updated

2023-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's disease

Interventions

Case series:NA

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) 18-70 years old; 2) patients who came to our hospital on time for IFX infusion according to the doctor's advice.

Exclusion criteria

Exclusion criteria: 1) serious underlying metabolic diseases (hypertension, hyperlipidemia, diabetes, cancer, etc.) that failed to be relieved by standardized clinical medication; 2) other biological agents were given before IFX infusion; 3) loss of response to IFX before enrollment.

Design outcomes

Primary

Measure	Time frame
loss response to infliximab;metabonomics;microbiomics;	—

Countries

China

Contacts

Public ContactKeyu Jia

Baoshan Branch of Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine

jky_candice@126.com+86 173 1716 9701

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026